Neil Lineberry

1.1k total citations
19 papers, 711 citations indexed

About

Neil Lineberry is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Neil Lineberry has authored 19 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 9 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Neil Lineberry's work include interferon and immune responses (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Ubiquitin and proteasome pathways (5 papers). Neil Lineberry is often cited by papers focused on interferon and immune responses (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Ubiquitin and proteasome pathways (5 papers). Neil Lineberry collaborates with scholars based in United States, Israel and Canada. Neil Lineberry's co-authors include C. Garrison Fathman, Leon Su, Galia Blum, Matthew Bogyo, Victoria E. Albrow, Margot G. Paulick, Laura E. Edgington‐Mitchell, Alicia B Berger, Luis Soares and Jack T. Lin and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Neil Lineberry

18 papers receiving 708 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Neil Lineberry United States 9 340 272 141 70 58 19 711
Susana Gordo United States 12 413 1.2× 400 1.5× 144 1.0× 50 0.7× 43 0.7× 14 913
Marianne Scheel Fjording Denmark 11 303 0.9× 238 0.9× 125 0.9× 51 0.7× 49 0.8× 17 610
Matthew R. Clutter United States 10 462 1.4× 243 0.9× 152 1.1× 106 1.5× 36 0.6× 17 720
Chudi Ndubaku United States 12 500 1.5× 375 1.4× 282 2.0× 28 0.4× 116 2.0× 22 932
Esther Llop Spain 18 642 1.9× 277 1.0× 148 1.0× 51 0.7× 98 1.7× 31 917
Luís Lima Portugal 20 586 1.7× 281 1.0× 205 1.5× 103 1.5× 75 1.3× 47 1.0k
Margaret S. Dordal United States 10 432 1.3× 215 0.8× 129 0.9× 47 0.7× 68 1.2× 12 822
Nicole Rufo Belgium 9 188 0.6× 309 1.1× 233 1.7× 115 1.6× 22 0.4× 10 615
William Riordan United States 9 300 0.9× 120 0.4× 132 0.9× 40 0.6× 21 0.4× 11 601
P Au Canada 6 419 1.2× 218 0.8× 100 0.7× 17 0.2× 39 0.7× 11 631

Countries citing papers authored by Neil Lineberry

Since Specialization
Citations

This map shows the geographic impact of Neil Lineberry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Lineberry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Lineberry more than expected).

Fields of papers citing papers by Neil Lineberry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Lineberry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Lineberry. The network helps show where Neil Lineberry may publish in the future.

Co-authorship network of co-authors of Neil Lineberry

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Lineberry. A scholar is included among the top collaborators of Neil Lineberry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Lineberry. Neil Lineberry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Porciuncula, Angelo, Vicky A. Appleman, Richard C. Gregory, et al.. (2024). Abstract 6732: Immunomodulatory and anti-tumor effect of a CCR2-targeted STING agonist iADC in human lung cancer. Cancer Research. 84(6_Supplement). 6732–6732. 1 indexed citations
3.
Rajasekaran, Karthik, Thomas J. Ow, Cherie‐Ann O. Nathan, et al.. (2023). Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.. Journal of Clinical Oncology. 41(16_suppl). 2579–2579. 2 indexed citations
4.
5.
Venkatakrishnan, Karthik, Neeraj Gupta, Patrick F. Smith, et al.. (2022). Asia‐Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo. Clinical Pharmacology & Therapeutics. 113(2). 298–309. 12 indexed citations
6.
7.
Hatton, Beryl A., Marc Grenley, Sally Ditzler, et al.. (2022). Abstract 620: Intratumoral microdosing via the CIVO® Platform reveals anti-tumor immune responses induced by the STING Agonist TAK-676 alone and in combination with chemotherapies. Cancer Research. 82(12_Supplement). 620–620. 1 indexed citations
8.
Appleman, Vicky A., Allison Berger, Emily Roberts, et al.. (2022). Abstract 3448: The IV STING agonist, TAK-676, enhances immune-mediated anti-tumor activity of radiation in syngeneic mouse models. Cancer Research. 82(12_Supplement). 3448–3448. 2 indexed citations
9.
10.
Falchook, Gerald S., Jason J. Luke, James Strauss, et al.. (2021). A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 39(15_suppl). TPS2670–TPS2670. 5 indexed citations
11.
Lineberry, Neil, Jesse A. Berlin, Michael Berkwits, et al.. (2016). Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. BMJ. 355. i5078–i5078. 70 indexed citations
12.
Lineberry, Neil, et al.. (2011). Pricing strategies for emerging markets. Nature Reviews Drug Discovery. 10(8). 567–567. 2 indexed citations
13.
Lin, Jack T., Neil Lineberry, Michael G. Kattah, et al.. (2009). Naive CD4 T Cell Proliferation Is Controlled by Mammalian Target of Rapamycin Regulation of GRAIL Expression. The Journal of Immunology. 182(10). 5919–5928. 37 indexed citations
14.
Edgington‐Mitchell, Laura E., Alicia B Berger, Galia Blum, et al.. (2009). Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nature Medicine. 15(8). 967–973. 241 indexed citations
15.
Lineberry, Neil, Leon Su, Luis Soares, & C. Garrison Fathman. (2008). The Single Subunit Transmembrane E3 Ligase Gene Related to Anergy in Lymphocytes (GRAIL) Captures and Then Ubiquitinates Transmembrane Proteins across the Cell Membrane. Journal of Biological Chemistry. 283(42). 28497–28505. 62 indexed citations
16.
Lineberry, Neil, Leon Su, Jack T. Lin, et al.. (2008). Cutting Edge: The Transmembrane E3 Ligase GRAIL Ubiquitinates the Costimulatory Molecule CD40 Ligand during the Induction of T Cell Anergy. The Journal of Immunology. 181(3). 1622–1626. 49 indexed citations
17.
Fathman, C. Garrison & Neil Lineberry. (2007). Molecular mechanisms of CD4+ T-cell anergy. Nature reviews. Immunology. 7(8). 599–609. 142 indexed citations
18.
Su, Leon, Neil Lineberry, Yul Huh, Luis Soares, & C. Garrison Fathman. (2006). A Novel E3 Ubiquitin Ligase Substrate Screen Identifies Rho Guanine Dissociation Inhibitor as a Substrate of Gene Related to Anergy in Lymphocytes. The Journal of Immunology. 177(11). 7559–7566. 62 indexed citations
19.
Lineberry, Neil & C. Garrison Fathman. (2006). T Cell Anergy: Where It's LAT. Immunity. 24(5). 501–503. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susana Gordo Breakdown of academic impact, for papers by Marianne Scheel Fjording Breakdown of academic impact, for papers by Matthew R. Clutter Breakdown of academic impact, for papers by Chudi Ndubaku Breakdown of academic impact, for papers by Esther Llop Breakdown of academic impact, for papers by Luís Lima Breakdown of academic impact, for papers by Margaret S. Dordal Breakdown of academic impact, for papers by Nicole Rufo Breakdown of academic impact, for papers by William Riordan Breakdown of academic impact, for papers by P Au
Rankless by CCL
2026